What changed in this filing

/stocks — the workspaceLOADING

Item 5. Other Information

2025-08-14 compared with 2025-05-13 · 26 added, 21 removed, 18 unchanged (72% of the section changed)

Other Information

Rule 10b5-1 Trading Plans – Directors

and Section 16 Officers

During the three months ended March 31, 2025,

none of the Company’s directors or Section 16 officers adopted or terminated any contract, instruction or written plan for the purchase

or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act or

any “non-Rule 10b5-1 trading arrangement”.

10b5-1 Trading Plans - Directors and Section 16 Officers

the three months ended March 31, 2025, none of the Company’s directors or Section 16 officers adopted or terminated any contract,

instruction or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions

of Rule 10b5-1(c) of the Exchange Act or any “non-Rule 10b5-1 trading arrangement”.

Plan Amendment

May 20, 2025, the Company's board of directors adopted the Second Amendment (the “Second Amendment” ) to

the Company’s Inducement Plan, increasing the aggregate number of shares of common stock that may be issued pursuant to equity

incentive awards under the Inducement Plan by 575,000 shares of common stock that may be issued pursuant to equity incentive awards under

the Inducement Plan.

The Company believes that the increase in the shares reserved under the Inducement Plan is necessary to allow it

to attract qualified employees.

foregoing description of the terms of the Second Amendment is qualified in its entirety by reference to the actual terms of the Second

Amendment, which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.

NeuroOne Medical Technologies Corporation

Certificate of Incorporation of NeuroOne Medical Technologies Corporation (incorporated by reference to Exhibit 3.4 on the Registrant’s Current Report on Form 8-K filed on June 29, 2017).

1 unchanged sentence

Amended and Restated Bylaws of NeuroOne Medical Technologies Corporation (incorporated by reference to Exhibit 3.1 on the Registrant’s Current Report on Form 8-K filed on June 21, 2024 ) .

NeuroOne Medical Technologies Corporation 2025 Equity Incentive Plan (incorporated by reference from Exhibit 10.1 to the Form 8-K filed on February 20, 2025).

NeuroOne Medical Technologies Corporation 2025 Equity Incentive Plan Form of Restricted Stock Unit Grant Agreement (incorporated by reference from Exhibit 10.2 to the Form 8-K filed on February 20, 2025).

NeuroOne Medical Technologies Corporation 2025 Equity Incentive Plan Form of Option Grant Agreement (incorporated by reference from Exhibit 10.3 to the Form 8-K filed on February 20, 2025).

Agreement, dated April 4, 2025, between NeuroOne Medical Technologies Corporation and Ladenburg Thalmann & Co.

Second Amendment to NeuroOne Medical Technologies Corporation 2021 Incentive Plan

Underwriting Agreement, dated April 4, 2025, between NeuroOne Medical Technologies Corporation and Ladenburg Thalmann & Co.

(incorporated by reference to Exhibit 1.1 on the Registrant’s Current Report on Form 8-K filed on April 7, 2025).

10 unchanged sentences

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

Filed herewith.

Documents are furnished and not filed.

NeuroOne Medical Technologies Corporation

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

are furnished and not filed.

NeuroOne Medical Technologies Corporation

/s/ David Rosa

Chief Executive Officer

(Principal Executive Officer)

/s/ Ronald McClurg

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by

the undersigned thereunto duly authorized.

August 14, 2025

Medical Technologies Corporation

Executive Officer

Executive Officer)

Ronald McClurg

Chief Financial Officer

(Principal Financial Officer and Principal Accounting Officer)

Financial Officer

Financial Officer and

Principal Accounting Officer)

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 5. Other Information